Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory

Expert Review of Molecular Diagnostics

Volumn 16, Issue 4, 2016, Pages 461-472

  Kanagal Shamanna, Rashmi ^a   Singh, Rajesh R ^a   Routbort, Mark J ^a   Patel, Keyur P ^a   Medeiros, L Jeffrey ^a   Luthra, Rajyalakshmi ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

clinical laboratory; hematologic malignancies; mutation; next generation sequencing; validation

Indexed keywords

ANALYTIC METHOD; CANCER DIAGNOSIS; CERTIFICATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LABORATORY; NEXT GENERATION SEQUENCING; PRACTICE GUIDELINE; REVIEW; STANDARDIZATION; VALIDATION PROCESS; DNA SEQUENCE; GENETICS; HEMATOLOGIC NEOPLASMS; HIGH THROUGHPUT SEQUENCING; MOLECULAR DIAGNOSIS; MUTATION; STANDARDS; VALIDATION STUDY;

TUMOR MARKER;

BIOMARKERS, TUMOR; HEMATOLOGIC NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; SEQUENCE ANALYSIS, DNA; VALIDATION STUDIES AS TOPIC;

EID: 84958051301     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1142374     Document Type: Review

References (74)

1. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363 (25): 2424-2433.
2. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368 (22): 2059-2074.
3. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutationsof splicing machinery in myelodysplasia. Nature. 2011; 478 (7367): 64-69.
4. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013; 368 (19): 1781-1790.
5. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475 (7354): 101-105.
6. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012; 367 (9): 826-833.
7. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364 (24): 2305-2315.
8. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122 (22): 3616-3627. quiz 3699.
9. Mardis ER. A decade's perspective on DNA sequencing technology. Nature. 2011; 470 (7333): 198-203.
10. Braggio E, Egan JB, Fonseca R, et al. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. 2013; 3: e127.
11. Gargis AS, Kalman L, Berry MW, et al. Assuring the quality of nextgeneration sequencing in clinical laboratory practice. Nat Biotechnol. 2012; 30 (11): 1033-1036.
12. Aziz N, Zhao Q, Bry L, et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015; 139 (4): 481-493.
13. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013; 15 (9): 733-747.
14. Kristensen T, Broesby-Olsen S, Vestergaard H, et al. Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis. Eur J Haematol. 2015 Jun 10 DOI: 10.1111/ejh.12601.
15. Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencingbased multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014; 99 (3): 465-473.
16. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2014; 16 (1): 56-67.
17. Bennett NC, Farah CS. Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel). 2014; 6 (4): 2296-2312.
18. Patnaik MM, Parikh SA, Hanson CA, et al. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014; 165 (3): 273-286.
19. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012; 119 (15): 3578-3584.
20. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122 (25): 4021-4034.
21. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. France: IARC Lyon; 2008.
22. Port M, Bottcher M, Thol F, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and metaanalysis. Ann Hematol. 2014; 93 (8): 1279-1286.
23. Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010; 28 (16): 2739-2747.
24. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol. 2009; 21 (6): 573-581.
25. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366 (12): 1079-1089.
26. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012; 120 (15): 2963-2972.
27. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012; 119 (24): 5824-5831.
28. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011; 25 (7): 1153-1158.
29. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125 (9): 1367-1376.
30. McWhinney SR, McLeod HL. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics. 2009; 10 (3): 489-493.
31. Brownstein CA, Beggs AH, Homer N, et al. An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY challenge. Genome Biol. 2014; 15 (3): R53.
32. Nickels EM, Soodalter J, Churpek JE, et al. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol. 2013; 4 (4): 254-269.
33. Weiss MM, Van Der Zwaag B, Jongbloed JDH, et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: A National Collaborative Study of Dutch Genome Diagnostic Laboratories. Human Mutation. 2013; 34 (10): 1313-1321.
34. Schrijver I, Aziz N, Jennings LJ, et al. Methods-based proficiency testing in molecular genetic pathology. J Mol Diagn. 2014; 16 (3): 283-287.
35. BioMed Valley Discoveries, Inc. Phase 1/2 dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of the ERK1/2 inhibitor BVD-523 in patients with acute myelogenous leukemia or myelodysplastic syndromes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Dec 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02296242. NLM Identifier: NCT02296242.
36. National Cancer Institute (NCI. A phase 2 study of MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in acute myeloid leukemia (AML) with RAS mutations. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US. 2000- [cited 2015 Dec 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01907815. NLM Identifier: NCT01907815.)
37. M.D. Anderson Cancer Center. Phase I/II trial of MEK inhibitor MEK162 in patients with relapsed and or refractory acute myeloid leukemia and patients with poor prognosis acute myeloid leukemia not suitable for or unwilling to receive standard therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Dec 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02089230. NLM Identifier: NCT02089230.)
38. Behdad A, Weigelin HC, Elenitoba-Johnson KS, et al. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms. J Mol Diagn. 2015; 17 (1): 76-84.
39. Meyer M, Stenzel U, Hofreiter M. Parallel tagged sequencing on the 454 platform. Nat Protoc. 2008; 3 (2): 267-278.
40. Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn. 2011; 11 (3): 333-343.
41. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009; 55 (4): 641-658.
42. Pant S, Weiner R, Marton MJ. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol. 2014; 4: 78.
43. Bragg LM, Stone G, Butler MK, et al. Shining a light on dark sequencing: characterising errors in Ion Torrent PGM data. PLoS Comput Biol. 2013; 9 (4): e1003031.
44. Abnizova I, Leonard S, Skelly T, et al. Analysis of context-dependent errors for illumina sequencing. J Bioinform Comput Biol. 2012; 10 (2): 1241005.
45. Park MH, Rhee H, Park JH, et al. Comprehensive analysis to improve the validation rate for single nucleotide variants detected by nextgeneration sequencing. PLoS One. 2014; 9 (1): e86664.
46. Salto-Tellez M. Gonzalez de Castro D. Next-generation sequencing: a change of paradigm in molecular diagnostic validation. J Pathol. 2014; 234 (1): 5-10.
47. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010; 12 (4): 425-432.
48. Kim SY, Speed TP. Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics. 2013; 14: 189.
49. Ding L, Wendl MC, McMichael JF, et al. Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet. 2014; 15 (8): 556-570.
50. Goode DL, Hunter SM, Doyle MA, et al. A simple consensus approach improves somatic mutation prediction accuracy. Genome Med. 2013; 5 (9): 90.
51. Zhang J, Chiodini R, Badr A, et al. The impact of next-generation sequencing on genomics. J Genet Genomics. 2011; 38 (3): 95-109.
52. Gowrisankar S, Lerner-Ellis JP, Cox S, et al. Evaluation of secondgeneration sequencing of 19 dilated cardiomyopathy genes for clinical applications. J Mol Diagn. 2010; 12 (6): 818-827.
53. Ye K, Schulz MH, Long Q, et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009; 25 (21): 2865-2871.
54. Chou LS, Liu CS, Boese B, et al. DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model. Clin Chem. 2010; 56 (1): 62-72.
55. Davis MP, Van Dongen S, Abreu-Goodger C, et al. Kraken: a set of tools for quality control and analysis of high-throughput sequence data. Methods. 2013; 63 (1): 41-49.
56. Lee LA, Arvai KJ, Jones D. Annotation of sequence variants in cancer samples: processes and pitfalls for routine assays in the clinical laboratory. J Mol Diagn. 2015; 17 (4): 339-351.
57. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008; 10 (4): 294-300.
58. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010; 11 (6): 415-425.
59. Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013; 160 (5): 660-672.
60. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119 (9): 2114-2121.
61. Shih AH, Chung SS, Dolezal EK, et al. Mutational analysis of therapyrelated myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013; 98 (6): 908-912.
62. Nabhan C, Raca G, Wang YL. Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol. 2015; 1 (7): 965-974.
63. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15 (7): 565-574.
64. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000; 15 (1): 7-12.
65. Human Genome Variation Society. Available from: http://www.hgvs. org/content/guidelines
66. Wain HM, Bruford EA, Lovering RC, et al. Guidelines for human gene nomenclature. Genomics. 2002; 79 (4): 464-470.
67. HUGO Gene Nomenclature Comittee. Available from: http://www. genenames.org.
68. Dalgleish R, Flicek P, Cunningham F, et al. Locus Reference Genomic sequences: an improved basis for describing human DNA variants. Genome Med. 2010; 2 (4): 24.
69. Danecek P, Auton A, Abecasis G, et al. The variant call format and VCFtools. Bioinformatics. 2011; 27 (15): 2156-2158.
70. Cock PJ, Fields CJ, Goto N, et al. The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants. Nucleic Acids Res. 2010; 38 (6): 1767-1771.
71. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25 (16): 2078-2079.
72. Hsi-Yang Fritz M, Leinonen R, Cochrane G, et al. Efficient storage of high throughput DNA sequencing data using reference-based compression. Genome Res. 2011; 21 (5): 734-740.
73. Lange T, Edelmann A, Siebolts U, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013; 98 (5): 722-728.
74. Kroger N, Alchalby H, Klyuchnikov E, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009; 113 (8): 1866-1868.